CX vs LIN

For growth investors, Linde plc (LIN) is the stronger pick with 3.

0% revenue growth year-over-year, versus -0. 1% for CEMEX, S. A. B. de C. V. (CX). CEMEX, S. A. B. de C. V. (CX) offers the better valuation at 2. 1x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate CEMEX, S. A. B. de C. V. (CX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CEMEX, S.

A. B. de C. V. (CX) is the cheapest at 2. 1x versus Linde plc at 34. 4x. On forward P/E, CEMEX, S. A. B. de C. V. is actually cheaper at 16. 8x.

Over the past 5 years, Linde plc (LIN) delivered a total return of +78.

1%, compared to +59. 7% for CEMEX, S. A. B. de C. V. (CX). Over 10 years, the gap is even starker: LIN returned +376. 9% versus CX's +110. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.

24β versus CEMEX, S. A. B. de C. V. 's 1. 17β — meaning CX is approximately 389% more volatile than LIN relative to the S&P 500. On balance sheet safety, CEMEX, S. A. B. de C. V. (CX) carries a lower debt/equity ratio of 56% versus 68% for Linde plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Linde plc (LIN) is pulling ahead at 3.

0% versus -0. 1% for CEMEX, S. A. B. de C. V. (CX). On earnings-per-share growth, the picture is similar: CEMEX, S. A. B. de C. V. grew EPS 982. 0% year-over-year, compared to 7. 1% for Linde plc. Over a 3-year CAGR, CX leads at 3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Linde plc (LIN) is the more profitable company, earning 20.

3% net margin versus 6. 0% for CEMEX, S. A. B. de C. V. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus 10. 0% for CX. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CEMEX, S.

A. B. de C. V. (CX) trades at 16. 8x forward P/E versus 28. 1x for Linde plc — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LIN: 7. 5% to $539. 71.

All stocks in this comparison pay dividends.

CEMEX, S. A. B. de C. V. (CX) offers the highest yield at 6. 5%, versus 1. 2% for Linde plc (LIN).

For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

24), 1. 2% yield, +376. 9% 10Y return). Both have compounded well over 10 years (LIN: +376. 9%, CX: +110. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CX is a small-cap deep-value stock; LIN is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.